# Myriad Genetics

its MyChoice CDx received FDA approval as the companion diagnostic for Zejula (niraparib) in ovarian cancer, and the company continues expanding its Precise MRD test into colorectal, renal and breast cancer.

Source: https://en.bioecon.ru/companies/myriad-genetics/
Updated: 2026-07-20

- Country: United States
- Ticker: MYGN

## Technologies

- [Companion diagnostics platforms](https://en.bioecon.ru/technology/companion-diagnostics-platforms/)